Menarini Silicon Biosystems

Today marks the begining of the Men's Breast Cancer Awareness Week. Over 2,700 men in the US will be diagnosed with breast cancer this year. We would like to take this opportunity to raise awareness for a devestating disease that brings with it a stigma when diagnosed in men, ultimatley leading to barries in detection and care (breastcancer.org). As a company, we renew our commitment to support research efforts around the world to advance knowledge and understanding on breast cancer #MaleBreastCancer, #Awareness

Multiple Myeloma is the second most common blood cancer and repeated bone marrow biopsies are the standard of care to monitor the disease over time.  The CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Enumeration assay directly measures levels of plasma cells in peripheral blood and provides new, complementary information with a minimally invasive procedure. Available as a CLIA lab service in the US. Available for biopharma research across Europe as a research lab service. https://lnkd.in/d9nY7rtS #LDT #MultipleMyeloma #LiquidBiopsy *The Circulating Multiple Myeloma Cell assay for CELLSEARCH® has not been cleared or approved by the FDA. In the US only it is available as a commercial, CLIA-approved assay that meet the certification standards of The Centers for Medicare and Medicaid Services.

October is Breast Cancer Awareness Month, an important occasion to raise awareness about the impact of breast cancer and share knowledge. We would like to recognize and thank the healthcare workers, caregivers, patients and advocates working together to battle this disease. As a company, we renew our commitment to support research efforts around the world to advance knowledge and understanding on breast cancer. #BreastCancer #Awareness

We offer global biopharma lab services leveraging the gold standard CELLSEARCH technology. Our unique menu of services including enumeration of Circulating Tumor Cells and phenotyping (HER2, PDL1), enumeration of Circulating Melanoma Cells and Circulating Multiple Myeloma Cells. UNIQUE Benefits • Gold Standard CTC Enumeration With THE CELLSEARCH® System • 96 or 120 hours sample stability from time of collection thanks to our proprietary CellSave and CellRescue tubes. • Capability to develop reproducible customized assays for specific biomarkers of interest. Get in contact to learn how we can support your clinical trial and research projects https://lnkd.in/dvEHcNy9 #labservices #biopharma #CTCtesting #clinical trial

A new review from the International Society of Liquid Biopsy is out exploring the latest advancements in Circulating Tumor Cell (CTC) research and suggesting future directions of investigation. The importance of concurrent evaluations of CTCs and other circulating biomarkers, particularly circulating tumor DNA, is highlighted in order to unlock the full clinical capabilities of liquid biopsy. https://lnkd.in/d6DwHVwh #CTC #LiquidBiopsy #20Anniversary #ISLB

Just published! A new proof-of-concept study explores the potential involvement of Circulating Multiple Myeloma Cells (CMMCs), counted via CELLSEARCH®, in monitoring multiple myeloma (MM) and smouldering MM (SMM) disease dynamics by measuring them during treatment and correlating the results with the prognoses of the patients. The results show that CMMC counts in the MM patients are correlated with clinical–biochemical features and suggest that persistence of CMMC during therapy is potentially linked to poor prognosis. https://lnkd.in/dRV3t8MZ #MultipleMyeloma #CMMC #LiquidBiopsy #CELLSEARCH

Multiple Myeloma is the second most common blood cancer and repeated bone marrow biopsies are the standard of care to monitor the disease over time. The CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Enumeration assay directly measures levels of plasma cells in peripheral blood and provides new, complementary information with a minimally invasive procedure. In the US, the test is available for physicians as a Laboratory-Developed Test (LDTs)* for patient management or for biopharma and clinical trials research as a CLIA-certified test. The test** is available for biopharma research across Europe as a research lab service. https://lnkd.in/d9nY7rtS #LDT #MultipleMyeloma #LiquidBiopsy *The Circulating Multiple Myeloma Cell assay for CELLSEARCH® has not been cleared or approved by the FDA. In the US only it is available as a commercial, CLIA-approved assay that meet the certification standards of The Centers for Medicare and Medicaid Services. **For Research use only.

For over 19 years, our labs have partnered with pharmaceutical and biotech companies to offer specialized lab services to expedite drug discovery and development programs from preclinical through Phase IV trials. Having processed over 25,000 samples and participated in almost 60 clinical trials, our labs have a proven track record of dependability and expertise that is evident in the successful completion of regulatory and and company audits that have resulted in zero major findings. Discover our Pharma Lab Services https://lnkd.in/dvEHcNy9 #pharma #drugdiscovery #biopharma #clinicalstudies #CRO

While Circulating Tumor Cells (CTCs) in metastatic breast cancer continue to be a strong marker of prognosis, evidence has documented that CTCs in patients with HER2-negative primary tumors can evolve to be HER2-positive, thus emphasizing the need to periodically monitor HER2 beyond the primary tumor. The CELLSEARCH CTC Enumeration test with HER2 measures HER2 protein expression of CTCs alongside our gold-standard enumeration assay. In the US, the test is available for physicians as a Laboratory-Developed Test (LDTs)* for patient management or for biopharma and clinical trials research as a CLIA-certified test. The HER2 assay data is reported as numbers of HER2+ CTC and total CTC/7.5 mL of whole blood. In Europe the test is available as a research use only lab service for biopharma and clincial trial. The CELLSEARCH HER2 tumor phenotyping reagent is also available as a Research Use Only product in Europe and Asia Pacific to be used in conjuction with the CELLSEARCH CTC kit. To learn more visit: https://lnkd.in/dPGqv26W #LDT #HER2 #Biomarker #LiquidBiopsy

Results of a large clinical validation study show that Menarini Silicon Biosystems' fetal cell based noninvasive prenatal screening (NIPT) technology can accurately detect both fetal genome-wide pathogenic copy number variants greater than 400Kb in size and the commonly screened trisomy conditions. Read the full release https://lnkd.in/eGVeqwZ3 #prenatal #rarecell #circulatingfetalcells